4.4 Article

Recovery of adrenal function after chronic secondary adrenal insufficiency in patients with hypopituitarism

Journal

CLINICAL ENDOCRINOLOGY
Volume 85, Issue 2, Pages 216-222

Publisher

WILEY-BLACKWELL
DOI: 10.1111/cen.13048

Keywords

-

Ask authors/readers for more resources

ObjectivePrevious studies have reported recovery of secondary adrenal insufficiency (SAI) in patients with pituitary disorders, generally immediately after pituitary surgery; however, data regarding recovery of long-term SAI are lacking. We conducted a study to assess the longer term recovery rate of SAI in patients with pituitary disorders. MethodsWe identified all SAI patients in the Halifax Neuropituitary Database from 1 November 2005 to 30 September 2014, who had required glucocorticoid therapy for 3 months, and had a minimum follow-up of 6 months. Patients with ACTH-secreting adenomas, those receiving glucocorticoids only in the routine peri-operative period for pituitary surgery and those on glucocorticoids for nonpituitary conditions were excluded. SAI was defined as either basal serum cortisol < 130 nm and/or a subnormal cortisol response to ACTH-(1-24) stimulation test or insulin tolerance test response. ResultsFifty-one patients fulfilled the criteria. Nine (176%) patients had complete recovery of SAI over a median of 20 months (range: 8-51) after initiating glucocorticoid replacement. Patients with smaller tumour size had increased likelihood of hypothalamic-pituitary-adrenal (HPA) axis recovery, whereas those with secondary hypogonadism or growth hormone deficiency were less likely to recover. Those with initial cortisol >175 nm had an almost one in two chance of recovery. ConclusionResults from our study show that approximately one in six patients with SAI recover adrenal function, even up to 5 years after diagnosis. We recommend that patients with SAI undergo regular testing to assess recovery in order to prevent unnecessary glucocorticoid therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Endocrinology & Metabolism

Coexistence of Myelolipoma and Primary Bilateral Macronodular Adrenal Hyperplasia With GIP-Dependent Cushing's Syndrome

Stephanie Larose, Louis Bondaz, Livia M. Mermejo, Mathieu Latour, Odile Prosmanne, Isabelle Bourdeau, Andre Lacroix

FRONTIERS IN ENDOCRINOLOGY (2019)

Article Endocrinology & Metabolism

Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease

John Newell-Price, Rosario Pivonello, Antoine Tabarin, Maria Fleseriu, Przemyslaw Witek, Monica R. Gadelha, Stephan Petersenn, Libuse Tauchmanova, Shoba Ravichandran, Pritam Gupta, Andre Lacroix, Beverly M. K. Biller

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2020)

Article Endocrinology & Metabolism

Pasireotide treatment significantly reduces tumor volume in patients with Cushing's disease: results from a Phase 3 study

Andre Lacroix, Feng Gu, Jochen Schopohl, Albert Kandra, Alberto M. Pedroncelli, Lixian Jin, Rosario Pivonello

PITUITARY (2020)

Article Endocrinology & Metabolism

Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study

A. Lacroix, M. D. Bronstein, J. Schopohl, T. Delibasi, R. Salvatori, Y. Li, A. Barkan, N. Suzaki, L. Tauchmanova, C-E Ortmann, S. Ravichandran, S. Petersenn, R. Pivonello

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2020)

Article Endocrinology & Metabolism

Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing's disease

Cedric Fontaine-Sylvestre, Laurent Letourneau-Guillon, Robert A. Moumdjian, France Berthelet, Andre Lacroix

Summary: This case report emphasizes the importance of monitoring ACTH and corticotroph tumor size in patients with persistent Cushing's disease, either under effective treatment with steroidogenesis inhibitors or after bilateral adrenalectomy.

PITUITARY (2021)

Editorial Material Medicine, General & Internal

Cardiometabolic Morbidity of Mild Cortisol Excess

Andre Lacroix

ANNALS OF INTERNAL MEDICINE (2022)

Article Endocrinology & Metabolism

Endogenous Cushing's syndrome during pregnancy

Nada Younes, Matthieu St-Jean, Isabelle Bourdeau, Andre Lacroix

Summary: Endogenous Cushing's syndrome during pregnancy is rare, commonly caused by adrenal adenomas and pregnancy-induced CS. Diagnosis is challenging due to physiologic hypercortisolism in pregnancy. Careful interpretation of cortisol production tests and limited imaging options are required. Surgical resection of lesions before 24 weeks of gestation is the optimal treatment, with metabolic complications managed in mild cases.

REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2023)

Review Endocrinology & Metabolism

Is Desmopressin Useful in the Evaluation of Cushing Syndrome?

Frederic Castinetti, Andre Lacroix

Summary: The desmopressin test has been used for the diagnosis of Cushing syndrome for the past 30 years. Although it has some merits, such as confirming the source of ACTH excess and evaluating the effectiveness of tumor resection, there is a lack of consensus on the criteria for normal or abnormal response to desmopressin. Further research is needed to determine its usefulness.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

Article Endocrinology & Metabolism

Genetic Dissection of Primary Aldosteronism in a Patient With MEN1 and Ipsilateral Adrenocortical Carcinoma and Adenoma

Stefanie Parisien La Salle, Gilles Corbeil, Zaki El-Haffaf, Caroline Duranceau, Mathieu Latour, Pierre Karakiewicz, Andre Lacroix, Isabelle Bourdeau

Summary: This case reports the first instance of adrenal collision tumors in a patient with a germline pathogenic variant of the MEN1 gene associated with MEN1 loss of heterozygosity in both oncocytic ACC and adenoma, as well as a somatic KCNJ5 pathogenic variant leading to aldosterone-producing adenoma. This case provides new insights into adrenal tumorigenesis in MEN1 patients.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

Review Endocrinology & Metabolism

Clinical, Pathophysiologic, Genetic, and Therapeutic Progress in Primary Bilateral Macronodular Adrenal Hyperplasia

Jerome Bertherat, Isabelle Bourdeau, Lucas Bouys, Fanny Chasseloup, Peter Kamenicky, Andre Lacroix

Summary: Patients with primary bilateral macronodular adrenal hyperplasia (PBMAH) have bilateral benign adrenocortical macronodules and variable levels of cortisol excess. Genetic mutations in ARMC5 and KDM1A genes are associated with PBMAH and can be detected through genetic analysis. Detailed assessment of PBMAH is crucial for management decisions, and treatment options include adrenalectomy, medical treatment with cortisol synthesis inhibitors, or specific blockers of aberrant GPCR.

ENDOCRINE REVIEWS (2023)

Editorial Material Endocrinology & Metabolism

Adrenal disorders in pregnancy

Adina F. F. Turcu, Andre Lacroix

Summary: This article highlights three major hurdles in understanding adrenal disorders in pregnant women: the overlap between pregnancy and adrenal pathology, the rare presentation of adrenal disorders during pregnancy, and the scarcity of human studies involving pregnant women. The lack of pregnancy-specific adrenal hormone calibrations makes the evaluation and management of adrenal disorders in pregnancy challenging. A collection of comprehensive articles by experts in adrenal physiology and pathology provides a valuable resource for healthcare providers at all stages and settings in addressing pregnancy-related adrenal pathology.

REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2023)

Review Endocrinology & Metabolism

Extensive expertise in endocrinology: glucose-dependent insulinotropic peptide-dependent Cushing's syndrome

Andre Lacroix

Summary: Thirty years ago, it was discovered that cortisol secretion in certain patients with adrenal disorders is stimulated by food intake due to abnormal adrenal response to increased glucose-dependent insulinotropic peptide (GIP). Ectopic GIP receptor (GIPR) expression was found in a limited number of cases, leading to the identification of various aberrant G-protein-coupled receptors involved in PBMAH or cortisol-secreting adenomas. In addition, ectopic GIPR was also found in other endocrine tumors. The elucidation of GIP-dependent diseases highlights the importance of personalized approaches to investigation and therapy for genetically determined conditions.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2023)

Review Endocrinology & Metabolism

Role of Adrenal Vein Sampling in Guiding Surgical Decision in Primary Aldosteronism

Nada Younes, Stephanie Larose, Isabelle Bourdeau, Eric Therasse, Andre Lacroix

Summary: Adrenal vein sampling (AVS) is recommended for subtyping primary aldosteronism (PA) to better guide individual management decisions. However, there is no consensus on AVS protocols, including sampling techniques, timing, and use of ACTH stimulation. Interpretation criteria for AVS also vary, leading to potential differences in clinical and biochemical outcomes. Recent pathological findings support the need for simultaneous bilateral sampling during AVS to properly evaluate selectivity, lateralization, and contralateral suppression.

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2023)

Article Endocrinology & Metabolism

Successful Adrenal Vein Sampling Using Dexamethasone Premedication in Patients With Iodine Contrast Media Allergy

Nada Younes, Eric Therasse, Isabelle Bourdeau, Andre Lacroix

Summary: This study evaluated the efficacy and safety of using high-dose dexamethasone premedication for AVS in patients with ICM allergy. The results showed that this method can diagnose the source of aldosterone excess in a safe and accurate manner.

JOURNAL OF THE ENDOCRINE SOCIETY (2022)

No Data Available